News Boehringer drug scores in rare kidney disease FSGS Boehringer's TRPC6 inhibitor apecotrep, formerly developed for COVID-19, has shown efficacy in the rare kidney disease FSGS in a phase 2 trial.
Patients Simplifying care to close the gap: Rethinking treatment burd... Simplifying the complexity of medical treatments extends beyond convenience to improving equity.
R&D GLP-1s in CKD: Evidence, market leadership, and key insights... At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight.
Events Partner Content 6th Antifibrotic Drug Development Summit Only cross-disease, cross-organ fibrosis summit
Patients Chronic kidney disease: treating a silent killer In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.